Flexion Therapeutics to Present at 14th Annual Needham Healthcare Conference

BURLINGTON, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:50 a.m. Eastern Time at The Westin NY Grand Central Hotel in New York, NY.

To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.

About Flexion Therapeutics

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained-release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

CONTACT: Media Contact
         Jamie Lacey-Moreira
         PressComm PR, LLC
         T: 410-299-3310
         [email protected]

         Corporate Contact
         Lisa Davidson, MBA
         Vice President, Finance and Administration
         Flexion Therapeutics, Inc.
         T: 781-305-7765
         [email protected]

You May Also Be Interested In

• Needham Starts Red Violet (RDVT) at Buy, 'offers the leading Cloud identity intelligence platform in the market today'
• Crexendo Again Earns Number 1 G2 Rankings Across UCaaS, VoIP and AI Categories
• Act Security Launches Amphi, a Free, Open-Source Toolkit to Take the Guesswork Out of Managing Cloud Access Policies